188 related articles for article (PubMed ID: 36566368)
1. Comparison of the side effects of antivirals in chronic hepatitis B patients: a single-center experience.
Gok Sargin Z; Celik U; Dusunceli I; Ustundag Y
Acta Gastroenterol Belg; 2022; 85(4):587-592. PubMed ID: 36566368
[TBL] [Abstract][Full Text] [Related]
2. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
3. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
4. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
[TBL] [Abstract][Full Text] [Related]
5. Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis.
Tong K; Chen M; Wang D; Dai H; Peng J; Zhang J; Zhou J; Chang Y; Huang W
Eur J Clin Pharmacol; 2024 Mar; 80(3):335-354. PubMed ID: 38197944
[TBL] [Abstract][Full Text] [Related]
6. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
[No Abstract] [Full Text] [Related]
9. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
10. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Pan CQ; Afdhal NH; Ankoma-Sey V; Bae H; Curry MP; Dieterich D; Frazier L; Frick A; Hann HW; Kim WR; Kwo P; Milligan S; Tong MJ; Reddy KR
Hepatol Commun; 2022 Aug; 6(8):1881-1894. PubMed ID: 35445803
[TBL] [Abstract][Full Text] [Related]
11. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Buti M; Marcos-Fosch C; Esteban R
Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis.
Ma X; Liu S; Wang M; Wang Y; Du S; Xin Y; Xuan S
J Clin Transl Hepatol; 2021 Jun; 9(3):335-344. PubMed ID: 34221919
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir.
Yuan GC; Chen AZ; Wang WX; Yi XL; Tu L; Peng F; Qiu ZH
World J Clin Cases; 2023 Dec; 11(34):8139-8146. PubMed ID: 38130795
[TBL] [Abstract][Full Text] [Related]
14. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
16. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Kumada T; Toyoda H; Yasuda S; Ito T; Tanaka J
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e898-e904. PubMed ID: 35048656
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
Liu R; Qiao J; Zhang L; Dou Z
Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
[TBL] [Abstract][Full Text] [Related]
18. [Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B].
Chang CD; Dong C; Zhao SX; Yuan XW; Zhang XX; Zhao DD; Dou Y; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):855-861. PubMed ID: 37723068
[No Abstract] [Full Text] [Related]
19. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
20. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Charlton MR; Alam A; Shukla A; Dashtseren B; Lesmana CRA; Duger D; Payawal DA; Duy Cuong D; Jargalsaikhan G; Cua IHY; Sollano JD; Singh KR; Madan K; Win KM; Kyi KP; Tun KS; Salih M; Rastogi M; Saraf N; Thuy PTT; Hien PTD; Gani RA; Mohamed R; Tanwandee T; Piratvisuth T; Sukeepaisarnjaroen W; Naing W; Hashmi ZY
J Gastroenterol; 2020 Sep; 55(9):811-823. PubMed ID: 32666200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]